Skip to content
LATEST
Health

Bayer completes Phase 3 Asundexian stroke-prevention trial

The placebo-controlled study covered patients after non-cardioembolic ischemic stroke or high-risk transient ischemic attack, a group at risk for recurrent…

Bayer completes Phase 3 Asundexian stroke-prevention trial

Bayer’s Phase 3 Asundexian trial, NCT05686070, was listed as completed with results on ClinicalTrials.gov on Nov. 20, according to the clinical registry.

The record marks a late-stage, placebo-controlled test of Asundexian (BAY2433334) in people after acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack, often called a mini-stroke.

The study evaluated whether Asundexian could help prevent ischemic stroke, which occurs when blood flow to part of the brain is blocked. Non-cardioembolic means the stroke was not attributed to a clot originating from the heart.

Bayer served as the trial sponsor. ClinicalTrials.gov identifies the intervention as Asundexian and the comparator as placebo, meaning participants in the control arm received an inactive treatment for comparison.

Phase 3 trials are late-stage human studies commonly used to assess whether a treatment works and to characterize safety before potential regulatory review. Completion of a Phase 3 trial does not by itself show that a drug is effective or safe.

The clinical importance of the record depends on the detailed outcome and safety data posted for NCT05686070 and any subsequent regulatory or company updates.

Source: clinical registry, ClinicalTrials.gov, Nov. 20, 2026

Atlas360 reports health research and does not provide medical advice.

More stories

Latest news